Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here. 		You are subscribed to Ophthalmology Times Europe.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
• Unoprostone in Phase III study
• Alternative IOL for sulcus fixation
• Triggerfish tolerable and safe
• Bevacizumab and diabetic neovascularization
 
 
Survey

Would you consider using unoprostone for retinal pigmentosa?

Click here to vote

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.
April 18, 2013
Unoprostone in phase III study for RP
Unoprostone will begin patient enrolment for the Phase III clinical study for the treatment of retinitis pigmentosa (RP). More...
Multifocal diffractive add-on IOL suitable alternative
Multifocal diffractive add-on IOL is a suitable alternative to standard multifocal IOLs for sulcus fixation. More...
Event Profile
Congress of the French Society of Ophthalmology — SFO 2013
Dates: 11–14 May 2013
Venue: Palais des Congrès, Paris
The Congress of the French Society of Ophthalmology is in its 119th year. The issues tackled in the main lectures include: advances in gene therapy, macular pathologies, childhood glaucoma, corneal ulcerations and management of conjunctival melanoma. There will also be interactive surgical workshops and over 100 exhibition stands. Read More
Pressure-sensitive lens tolerable and safe for 24 hours
A new pressure-sensitive contact lens is tolerable and safe over a 24-hour wearing period for healthy subjects and glaucoma sufferers, according to a paper in the Journal of Glaucoma. More...
Bevacizumab regresses abnormal diabetic neovascularization
Intravitreal bevacizumab is well tolerated and causes the regression of abnormal diabetic neovascularization, according to recently published data. More...